VIA
RXRX icon

Vident Investment Advisory’s Recursion Pharmaceuticals RXRX Stock Holding History

Vident Investment Advisory’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,849
Closed -$133K – 842
2023
Q2 		$133K Buy
17,849
+1,716
+11% +$12K ﹤0.01% 1108
2023
Q1 		$108K Buy
16,133
+2,552
+19% +$20.2K ﹤0.01% 1165
2022
Q4 		$105K Buy
13,581
+1,934
+17% +$19K ﹤0.01% 1104
2022
Q3 		$124K Buy
11,647
+1,166
+11% +$11.8K ﹤0.01% 1047
2022
Q2 		$85K Buy
+10,481
New +$70.1K ﹤0.01% 1210

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vident Investment Advisory's RXRX Position: Q3 2023 in Review

Vident Investment Advisory sold out of Recursion Pharmaceuticals (RXRX) in Q3 2023, closing a stake of 17,849 shares — an estimated $133K sold.

Vident Investment Advisory first reported a position in RXRX in Q2 2022 and held it in 5 quarters. The position peaked at $133K in Q2 2023. 192 funds tracked by Wall St. Rank hold RXRX as of Q3 2023.

  • Vident Investment Advisory reported no remaining Recursion Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 17,849 Recursion Pharmaceuticals shares in Q3 2023, an estimated $133K.
  • Vident Investment Advisory first reported a position in Recursion Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Vident Investment Advisory's Recursion Pharmaceuticals position peaked at $133K in Q2 2023.
  • 192 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.